Bavarian Biotech Report 2011/2012 (7MB) - Bio M

Myriad GmbHBIOTECH THERAPEUTICS & DIAGNOSTICSKeywords: Genomics, Biomarker, Molecular Diagnostics, PersonalizedMedicine, OncologyMyriad is a leading molecular diagnostic company based in Salt Lake City,Utah. The Company cites its mission as, “making a difference in patient’slives through the discovery and commercialization of transformative tests toassess a person’s risk of developing disease, guide treatment decisions andassess risk of disease progression and recurrence.” Originally founded in1991, Myriad has spent the last twenty years investing in the education ofpatients and health care providers on the role genes play in hereditary breast,colon, endometrial, ovarian, pancreatic, and skin cancers.Since 2011/2012 Myriad is building on this strong tradition by extendingtheir mission to Europe, in an effort to broaden the Company’s geographicfootprint and provide critical information to more patients and healthcareproviders. The central european laboratory of Myriad GmbH has opened inMartinsried/Munich in March 2012. The Company plans to offer itsBRACAnalysis ® test for genetic predisposition to breast and ovarian cancer,its Colaris ® test for genetic predisposition to colon and endometrial cancer,and the Colaris AP ® test for genetic predisposition to polyposis colon cancer.In addition to the laboratory in Munich, the Company has set up itsEuropean headquarters in Zurich, Switzerland and regional offices in Paris,France, Madrid, Spain, and Milan, Italy.Contact:Dr. Heinz OehlBunsenstr. 7D-82152 Planegg-MartinsriedPhone: +49 (0) 89 8757 8189Fax: +49 (0) 89 8757 8170E-Mail: hoehl@myriad.comInternet: www.myriad.comNanion Technologies GmbHBIOTECH DEVICES & REAGENTSKeywords: Nanobiotechnology, DevicesNanion Technologies is a spin-off from the Center for Nanoscience (CeNS)of the Ludwig-Maximilians-University of Munich (LMU). Nanion combinesbio- and microtechnology in a company serving the life sciences industry byoffering products and services which will dramatically increase the speedand efficiency of the drug discovery process in an important segment of thepharmaceutical market. Nanion bases its business on a proprietary chiptechnology and will design and develop High Throughput Screening (HTS)systems for ion channel active drugs (ICADs). Ion channels are prime targetsfor innovative medicines aimed at many important diseases.Contact:Dr. Niels FertigGabrielenstr. 9D-80636 MünchenPhone: +49 (0) 89 2189979-72Fax: +49 (0) 89 2189979-60E-Mail: info@nanion.deInternet: www.nanion.de91